 At one of the patients in Europe, we have a programme called the Myeloma Axis Atlas where we've mapped access to 31 drug combinations across Europe that are licensed by the European Medicine Agency. And what we can see is that many countries do really well in terms of access like Germany, France and Austria and other countries such as non-EU Balkan countries are almost 10 years behind the standard of care. So there are huge inequalities and many countries don't make the standard of care set out by EHA as my guidelines, which are universally agreed by the Myeloma political communities. So in terms of the access inequalities, I think they are varying in quite profound access challenges and what we need to do as an advocacy community, both in Myeloma and further a field, is to generate data to understand what the challenges are because in order to address challenges you need to know exactly what the situation is on the ground and then you can begin conversations and raise awareness of the issues that we need to tackle as a community. So our role is multi-batteted so we need to generate data to support our members. We need to provide one-to-one support to our members to help them understand what the access challenges are and also think about individual strategies to address them. We also have a big role to play with raising awareness with policymakers at the European level and working with the pharmaceutical industry, Hayards, HTA, re-embarkant bodies to really think about solutions to some of the situation that we're seeing at a national level and also to collaborate across communities to make sure that we're tackling these issues to improve patient outcomes.